Anavex Life Sciences (AVXL) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tenaya Therapeutics (TNYA) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 70.3% versus a loss of 84.3%. Over five years, AVXL leads with a -91.5% price change compared with -97.4% for TNYA. Anavex Life Sciences is the larger company by market cap ($138.1 million vs $130.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | TNYA |
|---|---|---|
| Share price | $1.49 | $0.5803 |
| Market cap | $138.12M | $130.12M |
| 1-day change | -3.25% | +6.63% |
| YTD return | -58.15% | -23.57% |
| 1-year return | -84.35% | -70.26% |
| 5-year return | -91.50% | -97.35% |
| EPS (TTM) | $-0.14 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.53 | $2.35 |
| 52-week low | $1.44 | $0.521 |
| Distance from 52-week high | -84.36% | -75.31% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | — | +451.44% |
| Average volume | 979.69K | 2.27M |
| Shares outstanding | 92.70M | 224.23M |
| Employees | 34 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNYA has outperformed AVXL by 14.1 percentage points over the past year.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
AVXL vs TNYA FAQ
Which is bigger, Anavex Life Sciences or Tenaya Therapeutics?
Anavex Life Sciences (AVXL) is larger, with a market capitalization of $138.12M compared with $130.12M for Tenaya Therapeutics (TNYA).
Which stock has performed better over the past year, AVXL or TNYA?
TNYA returned -70.26% over the past 12 months, compared with -84.35% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.